Published in

American Medical Association, JAMA Neurology, 7(80), p. 659, 2023

DOI: 10.1001/jamaneurol.2023.0815

Links

Tools

Export citation

Search in Google Scholar

Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?

Journal article published in 2023 by Vincent Planche ORCID, Nicolas Villain
Distributing this paper is prohibited by the publisher
Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

This Viewpoint discusses the benefits of clinical trials with a delayed-start design and analysis of downstream biomarkers to examine whether antimyeloid immunotherapy changes the course of early Alzheimer disease.